Ability to do pushups may predict cardiovascular risk

MARIA COHUT | February 19, 2019

article image
A new study suggests that the more pushups a man is able to complete, the lower his cardiovascular risk and vice versa. These findings may establish a new measure of risk assessment that is simple and does not require costly specialized equipment. World Health Organization (WHO) data indicate that every year there are 17.9 million deaths due to cardiovascular diseases (CVDs), accounting for approximately 31 percent of global deaths.

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

OTHER ARTICLES

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 20, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Spotlight

Hansyn Pharmaceutical Co., Ltd.

Hansyn Pharmaceutical Co., Ltd is a pharmaceutical company committed to increasing access to high-quality healthcare by development and manufacture of generic drugs of active pharmaceutical ingredients. Hansyn has cGMP veterinary drug production falicities and associated infra-structures producing veterinary ingredients such as Florfenicol and Thiamphenicol. Since 2012, Hansyn is entering human pharmaceutical area by investment of new cGMP multi-purpose plants (large scale plant, small scale plant, steroid plant), utility facilities, QC laboratories and R&D Centers, planned to be finished by 2013.

Events